Linked Life Data

19450630

Source:http://linkedlifedata.com/resource/pubmed/id/19450630

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
33
pubmed:dateCreated
2009-7-3
pubmed:abstractText
Since the introduction to the Swiss market in 1997, Crucell (former Berna Biotech Ltd.), has sold over 41 million doses worldwide of the virosomal adjuvanted influenza vaccine, Inflexal V. Since 1992, 29 company sponsored clinical studies investigating the efficacy and safety of Inflexal V have been completed in which 3920 subjects participated. During its decade on the market, Inflexal V has shown an excellent tolerability profile due to its biocompatibility and purity. The vaccine contains no thiomersal or formaldehyde and its purity is reflected in the low ovalbumin content. By mimicking natural infection, the vaccine is highly efficacious. Inflexal V is the only adjuvanted influenza vaccine licensed for all age groups and shows a good immunogenicity in both healthy and immunocompromised elderly, adults and children. This review presents and discusses the experience with Inflexal V during the past decade.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1873-2518
pubmed:author
pubmed:issnType
Electronic
pubmed:day
16
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4381-7
pubmed:dateRevised
2009-8-20
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine.
pubmed:affiliation
Berna Biotech AG, Rehhagstrasse 79, 3018 Berne, Switzerland. christian.herzog@crucell.ch
pubmed:publicationType
Journal Article, Review